NYSE:BTX Brooklyn ImmunoTherapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Brooklyn ImmunoTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.55 0.00 (0.00%) (As of 06/29/2022 04:00 PM ET) Add Compare Share Today's Range$0.52▼$0.5750-Day Range$0.48▼$1.3552-Week Range$0.46▼$21.03Volume260,463 shsAverage Volume507,665 shsMarket Capitalization$31.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BTX Stock Forecast (MarketRank)Overall MarketRank™0.00 out of 5 starsMedical Sector1420th out of 1,433 stocksBiotechnology Industry6th out of 8 stocksAnalyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Brooklyn ImmunoTherapeutics. Previous Next 0.0 Community Rank Outperform VotesBrooklyn ImmunoTherapeutics has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBrooklyn ImmunoTherapeutics has received 2 “underperform” votes. (Add your “underperform” vote.)Community SentimentBrooklyn ImmunoTherapeutics has received 100.00% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Brooklyn ImmunoTherapeutics and other stocks. Vote “Outperform” if you believe BTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBrooklyn ImmunoTherapeutics does not currently pay a dividend.Dividend GrowthBrooklyn ImmunoTherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Brooklyn ImmunoTherapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About Brooklyn ImmunoTherapeutics (NYSE:BTX)Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.Read More BTX Stock News HeadlinesJune 4, 2022 | americanbankingnews.comBrooklyn ImmunoTherapeutics (NYSE:BTX) Trading Down 0.8%See More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSE:BTX CUSIPN/A CIK748592 Webwww.brooklynitx.com Phone212 582 1199FaxN/AEmployees10Year FoundedN/ACompany Calendar Last Earnings4/15/2022Today6/29/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares57,452,000Free FloatN/AMarket Cap$31.60 million OptionableOptionable BetaN/A Brooklyn ImmunoTherapeutics Frequently Asked Questions How has Brooklyn ImmunoTherapeutics' stock price performed in 2022? Brooklyn ImmunoTherapeutics' stock was trading at $2.05 on January 1st, 2022. Since then, BTX stock has decreased by 73.2% and is now trading at $0.55. View the best growth stocks for 2022 here. How were Brooklyn ImmunoTherapeutics' earnings last quarter? Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) announced its quarterly earnings data on Friday, April, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. View Brooklyn ImmunoTherapeutics' earnings history. Who are Brooklyn ImmunoTherapeutics' key executives? Brooklyn ImmunoTherapeutics' management team includes the following people: Dr. Kevin A. D'Amour Ph.D., Chief Scientific Officer (Age 49, Pay $448.62k)Dr. Roger Sidhu M.D., Chief Medical Officer (Age 46, Pay $501.95k)Dr. Matthew Angel Ph.D., CEO & Director (Age 41)Mr. Andrew C. Jackson, Chief Financial Officer (Age 53)Dr. Monil Shah M.B.A., Pharm.D., Chief Operating OfficerMs. Sandra M. Gurrola, Principal Accounting Officer & VP of Fin. (Age 55)Mr. Jay Sial, Chief Admin. Officer (Age 57)Ms. Lynn Sadowski Mason M.S., Exec. VP of Clinical Operations (Age 43)Ms. Susan McClatchey, VP & Head of Quality Who are some of Brooklyn ImmunoTherapeutics' key competitors? Some companies that are related to Brooklyn ImmunoTherapeutics include Tiziana Life Sciences (TILS), ImmunoPrecise Antibodies (IPA), Novacyt (NCYT), Verseon (VSN), Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), Aptose Biosciences (APS), Arecor Therapeutics (AREC), e-therapeutics (ETX), Mereo BioPharma Group plc (MPH.L) (MPH), Medicenna Therapeutics (MDNA) and IntelGenx Technologies (IGX). View all of BTX's competitors. What is Brooklyn ImmunoTherapeutics' stock symbol? Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "BTX." How do I buy shares of Brooklyn ImmunoTherapeutics? Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Brooklyn ImmunoTherapeutics' stock price today? One share of BTX stock can currently be purchased for approximately $0.55. How much money does Brooklyn ImmunoTherapeutics make? Brooklyn ImmunoTherapeutics (NYSE:BTX) has a market capitalization of $31.60 million. How many employees does Brooklyn ImmunoTherapeutics have? Brooklyn ImmunoTherapeutics employs 10 workers across the globe. How can I contact Brooklyn ImmunoTherapeutics? The official website for Brooklyn ImmunoTherapeutics is www.brooklynitx.com. The company can be reached via phone at 212 582 1199. This page (NYSE:BTX) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here